enrofloxacin has been researched along with Osteosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rebhun, RB; Seo, KW; Watson, KD; Withers, SS; York, D | 1 |
| Chen, X; Holt, R; Jung, YS; Rebhun, RB; Rodriguez, CO; Seo, Kw | 1 |
2 other study(ies) available for enrofloxacin and Osteosarcoma
| Article | Year |
|---|---|
Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Cell Line, Tumor; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Doxorubicin; Enrofloxacin; Fluoroquinolones; Osteosarcoma; Tumor Suppressor Protein p53 | 2017 |
Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ciprofloxacin; Cyclin-Dependent Kinase Inhibitor p21; Dogs; Enrofloxacin; Enzyme Activation; Fluoroquinolones; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; M Phase Cell Cycle Checkpoints; Osteosarcoma; Phosphorylation; S Phase Cell Cycle Checkpoints | 2012 |